Abstract The development of targeted therapies for the treatment of myelofibrosis highlights a unique issue in a field that has historically relied on symptom relief, rather than survival benefit or modification of disease course, as key response criteria. There is, therefore, a need to understand what constitutes disease modification of myelofibrosis to advance appropriate drug […]
Curcumin Induces Cell Death in JAK2 Mutated Cells by Inhibition of JAK2/STAT and mTORC1 Pathways
Publisher’s Note by David Wallace: The two studies below provide compelling data on the effectiveness of supplementation with curcumin in patients with MPN. Although no recent studies on curcumin have emerged in MPN (since 2019), it would seem prudent to discuss the supplement with your physician. Naturally if you are taking any type of blood […]
MPN Clinical Trials, 2022 Update
MPN Clinical Trial update with Dr. Abu-Zeinah, from ASH 2021 by David Wallace TRANSCRIPT | MPN Clinical Trials, 2022 Update David Wallace: Hello, I’m David Wallace, founder of PV Reporter and our nonprofit organization MPN Cancer Connection. And your host for today’s program, the American Society of Hematology 2021 update, is Dr. Ghaith Abu-Zeinah from […]
Jazz great Ron Miles dies due to complications from blood cancer Polycythemia Vera
Ron Miles, legendary Denver-based jazz musician, educator and prolific recording and stage artist has died at 58. His death was confirmed by his label, NY-based Blue Note Records. According to a publicist there, Miles’ manager and producer Hans Wendl said that Miles died shortly before midnight on Tuesday, March 8 at his home in Denver […]
Preclinical studies of Flonoltinib Maleate, novel JAK2/FLT3 inhibitor treatment for MPNs
Abstract Janus kinase 2 (JAK2) hyperactivation by JAK2V617F mutation leads to myeloproliferative neoplasms (MPNs) and targeting JAK2 could serve as a promising therapeutic strategy for MPNs. Here, we report that Flonoltinib Maleate (FM), a selective JAK2/FLT3 inhibitor, shows high selectivity for JAK2 over the JAK family. Surface plasmon resonance assays verified that FM had a stronger affinity […]
Has PV become a disease of the middle-aged?
by David Wallace Dr. Ghaith Abu-Zeinah, Assistant Professor at Weill Cornell Medical College, Silver MPN Center is our MPN specialist answering this important question. David Wallace, PV Reporter, is your host and patient advocate. TRANSCRIPT | Has PV become a disease of the middle-aged? David: For many years PV been considered an older person’s disease. […]
Momelotinib: emerging treatment for myelofibrosis patients with anemia
Abstract The suite of marked anemia benefits that momelotinib has consistently conferred on myelofibrosis (MF) patients stem from its unique inhibitory activity on the BMP6/ACVR1/SMAD and IL-6/JAK/STAT3 pathways, resulting in decreased hepcidin (master iron regulator) expression, higher serum iron and hemoglobin levels, and restored erythropoiesis. Clinical data on momelotinib from the phase 2 and the […]
Pevonedistat targets malignant cells in myeloproliferative neoplasms
Key Points Pevonedistat targets the NFκB pathway to inhibit growth of MPN and sAML cells. Pevonedistat reduces disease burden in MPN mouse models. Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition Abstract Targeted inhibitors of JAK2 (eg ruxolitinib) often provide symptomatic relief for myeloproliferative neoplasm (MPN) patients, but the malignant clone […]
BESREMi, Ropeginterferon FDA approved Treatment for PV
by David Wallace Patients are Asking – MPN Expert Dr. Ghaith Abu-Zeinah discusses Ropeginterferon (BESREMi), new Treatment for Polycythemia Vera Episode 3 of 3 Ropeginterferon / BESREMi was recently approved by the FDA to treat polycythemia vera. Should I switch from Pegasys to the new FDA approved interferon? How might BESREMi change the treatment paradigm […]
New Horizons in MPN Treatment, A Review of Therapeutic Options
Abstract Philadelphia-negative myeloproliferative neoplasms (MPN) are aggressive diseases characterized by clonal proliferation of myeloid stem cells. The clonal process leads to excessive red cells production, platelets production, and bone marrow fibrosis. According to the phenotype, MPN can be classified as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPN patients have shortened survival […]
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 20
- Next Page »
